The project aimed to test a strategy for the early detection and prevention of tuberculosis in household contacts of tuberculosis patients in order to reduce the morbidity, mortality and transmission of this disease in Thailand. This strategy will be evaluated in comparison with the current programmatic approach through a pragmatic trial with cluster randomization (cluster randomized controlled trial) which will be conducted over the next 3 years. This project is carried out in collaboration with the Tuberculosis Division of the Ministry of Public Health of Thailand, the TB/HIV Research Foundation in Thailand and the London School of Hygiene and Tropical Medicine in England.
Title: Implementation of a new Strategic TB Case-Finding, Treatment and Prevention Public Health Pack in Thailand (CapThai) Phase: IV, cluster randomized trial Population: adults (\>= 18 years old) with pulmonary TB and their household contacts. Sites: 20 clusters (provincial hospitals) in Thailand Duration of the study: 36 months Subject participation duration: 9 months Description of the intervention: Combined active case-finding, treatment and prevention of TB amongst household contacts of TB cases, associated with initiation of SOC treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country. Overall objective: To evaluate whether a public health intervention package focusing on the households of newly detected TB cases can increase active case-finding and uptake of TB preventive therapy in Thailand. Specific objectives: 1. to compare the initiation and completion of TPT regimens amongst household contacts of infectious TB patients, overall and by gender and age group; 2. to evaluate the safety of short TPT regimens amongst HH contacts, overall and by gender and age group; 3. to compare the detection of TB and treatment uptake for active TB amongst HH contacts of infectious TB patients, overall and by gender and age group; 4. to assess the feasibility of the combined intervention among health care providers and beneficiaries, by gender and age group; 5. to assess the acceptability of the combined intervention among health care providers and beneficiaries, by gender and age group; 6. to evaluate the epidemiological impact of the combined intervention. Study design: The study uses a Stepped-Wedge Cluster Randomised Trial design. Randomisation will take place at the hospital level (cluster: provincial hospitals with \>150 new TB cases/year). Twenty clusters will be enrolled and switch from the control to the intervention phase in four sequences every 3 months in a random order until all clusters are exposed to the intervention. 1. Intervention Phase: Newly detected bacteriologically confirmed TB patients (≥ 18 years) will be sensitized on the importance of HH contact investigation and TB stigma reduction. They will be asked to enumerate all contacts (name/age/sex/relationship) living in their HH for\>1 month at the date of TB diagnostic. Screening invitation cards will be provided for each HH contact (or caregiver for children \<13 years old), inviting them to attend the TB clinic at the selected hospital for free screening and evaluation. Transportation fees will be provided. Contacts detected with active TB will receive recommended treatment. In contacts for whom active TB is formally excluded, TPT will be initiated with the new short regimens: (i) children \<2 years: isonicotine hydrazine (INH)+rifampicin daily for 3 months; (ii) children 2-12 years: INH+rifapentine weekly for 3 months; (iii) children≥13 and adults: INH+rifapentine daily for 1 month. 2. Control phase: current strategy relying on passive case detection and advice provided to TB patients to refer HH contacts to the TB clinic for screening. The index TB patient will be asked to enumerate HH contacts as above and inform them on the need to be screened at the TB clinic. Endpoints: Primary endpoint: Proportion of HH contacts with active TB excluded who are initiated on TPT within 4 weeks of the index TB patient diagnosis - overall, by age group (\<15, ≥15 years) and gender. Secondary endpoints: 1. Proportion of participants initiated on TPT who completed TPT; 2. Proportion of participants in the Intervention phase who were initiated on TPT for whom treatment is discontinued due to intolerance, adverse events, or severe adverse events; 3. Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 8 weeks of the index TB case diagnosis - overall, by age group (\<15, ≥15 years) and gender; 4. Proportion of household contacts diagnosed with TB who completed TB treatment in the intervention vs. control phase; 5. Proportion of contacts receiving TPT who developed TB over the 9 months follow-up period in the intervention vs. control phase. Estimated time to complete enrollment: 12-15 months
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
10,000
Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - overall
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - overall
Time frame: Month18
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by age group (<15, ≥15 years)
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by age group (\<15, ≥15 years)
Time frame: Month18
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by gender
Proportion of household contacts with active tuberculosis excluded who are initiated on tuberculosis preventive treatment within 4 weeks of the index tuberculosis patient diagnosis - by gender
Time frame: Month18
Proportion of participants initiated on TPT who completed TPT
Proportion of participants initiated on TPT who completed TPT
Time frame: Month 18
Proportion of participants who initiate TPT for whom treatment is discontinued due to adverse events or intolerance in the Intervention phase
Proportion of participants who initiate TPT for whom treatment is discontinued due to adverse events or intolerance in the Intervention phase
Time frame: Month 18
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - overall
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - overall
Time frame: Month 18
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by age group (<15, ≥15 years)
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by age group (\<15, ≥15 years)
Time frame: Month 18
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by gender
Proportion of HH contacts with newly diagnosed active TB initiated on curative treatment within 4 weeks of the index TB patient diagnosis - by gender
Time frame: Month 18
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.